4.7 Article

DNA Methylation as an Adjunct to Histopathology to Detect Prevalent, Inconspicuous Dysplasia and Early-Stage Neoplasia in Barrett's Esophagus

期刊

CLINICAL CANCER RESEARCH
卷 19, 期 4, 页码 878-888

出版社

AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1078-0432.CCR-12-2880

关键词

-

类别

资金

  1. Trinity College Cambridge
  2. NHS National Institute for Health Research
  3. Experimental Cancer Medicine Centre Network
  4. National Institute for Health Research Cambridge Biomedical Research Centre
  5. Cambridge Commonwealth Trust
  6. MRC programme grant
  7. MRC [MC_U105260799, MC_U105365007, MC_UU_12022/2] Funding Source: UKRI
  8. Medical Research Council [MC_UU_12022/2, MC_U105260799, MC_U105365007] Funding Source: researchfish
  9. National Institute for Health Research [NIHR-RP-02-12-011] Funding Source: researchfish

向作者/读者索取更多资源

Purpose: Endoscopic surveillance of Barrett's esophagus is problematic because dysplasia/early-stage neoplasia is frequently invisible and likely to be missed because of sampling bias. Molecular abnormalities may be more diffuse than dysplasia. The aim was therefore to test whether DNA methylation, especially on imprinted and X-chromosome genes, is able to detect dysplasia/early-stage neoplasia. Experimental design: 27K methylation arrays were used to find genes best able to differentiate between 22 Barrett's esophagus and 24 esophageal adenocarcinoma (EAC) samples. These were validated using pyrosequencing on a retrospective cohort (60 Barrett's esophagus, 36 dysplastic, and 90 EAC) and then in a prospective multicenter study (98 Barrett's esophagus patients, including 28 dysplastic and 9 early EAC) designed to utilize biomarkers to stratify patients according to their prevalent dysplasia/EAC status. Results: Genes (23%) on the array, including 7% of X-linked and 69% of imprinted genes, have shown statistically significant changes in methylation in EAC versus Barrett's esophagus (Wilcoxon P < 0.05). 6/7 selected candidate genes were successfully internally (Pearson's P < 0.01) and externally validated(ANOVAP < 0.001). Four genes (SLC22A18, PIGR, GJA12, and RIN2) showed the greatest area under curve (0.988) to distinguish between Barrett's esophagus and dysplasia/EAC in the retrospective cohort. This methylation panel was able to stratify patients from the prospective cohort into three risk groups based on the number of genes methylated (low risk: < 2 genes, intermediate: 2, and high: > 2). Conclusion: Widespread DNA methylation changes were observed in Barrett's carcinogenesis including approximate to 70% of known imprinted genes. A four-gene methylation panel stratified patients with Barrett's esophagus into three risk groups with potential clinical utility. Clin Cancer Res; 19(4); 878-88. (C) 2012 AACR.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据